We are live on
!
Find out more
Perceptive Advisors Portfolio holdings
AUM
$6.66B
Turnover
32.23%
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+13.54%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$5.12B
AUM Growth
-$493M
(-8.8%)
Cap. Flow
-$685M
Cap. Flow
% of AUM
-13.38%
Top 10 Holdings %
Top 10 Hldgs %
51.39%
Holding
136
New
20
Increased
23
Reduced
33
Closed
42
Avg Time Held Equity + Options
1.5
years
Top 10 Avg Time Held Equity + Options
0.7
years
Top 20 Avg Time Held Equity + Options
0.7
years
Avg Time Held Equity only
1.6
years
Top 10 Avg Time Held Equity only
0.7
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$101M |
| 2 |
Relay Therapeutics
RLAY
|
+$70.2M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$59.9M |
| 4 |
Ionis Pharmaceuticals
IONS
|
+$39.8M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$33.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Exact Sciences
EXAS
|
+$122M |
| 2 |
Arcellx
ACLX
|
+$95.6M |
| 3 |
Boston Scientific
BSX
|
+$93.3M |
| 4 |
Amicus Therapeutics
FOLD
|
+$90.7M |
| 5 |
Astria Therapeutics
ATXS
|
+$84.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.61% |
| 2 | Miscellaneous | 1.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
126
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.9B
| – | – |
-1,100,000
| Closed | -$134M | – |
|
127
Xenon Pharmaceuticals
XENE
$3.32B
| – | – |
-200,791
| Closed | -$9M | – |
|
128
LENZ Therapeutics
LENZ
$112M
| – | – |
-50,000
| Closed | -$800K | – |
|
129
CALL
Tectonic Therapeutic
TECX
$416M
| – | – |
-250,000
| Closed | -$5.21M | – |
|
130
GRAIL Inc
GRAL
$6.05B
| – | – |
-237,342
| Closed | -$20.3M | – |
|
131
Septerna Inc
SEPN
$1.75B
| – | – |
-433,160
| Closed | -$12.1M | – |
|
132
Palvella Therapeutics
PVLA
$1.83B
| – | – |
-266,287
| Closed | -$27.9M | – |
|
133
Kestra Medical Technologies
KMTS
$1.71B
| – | – |
-285,000
| Closed | -$7.56M | – |
|
134
Caris Life Sciences
CAI
$8.98B
| – | – |
-1,136,206
| Closed | -$30.7M | – |
|
135
MapLight Therapeutics
MPLT
$446M
| – | – |
-550,000
| Closed | -$9.66M | – |
|
Similar funds
Perceptive Advisors's Q1 2026 Portfolio in Review
As of Q1 2026, Perceptive Advisors held 136 positions worth $5.12B, down 8.8% from $5.61B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Perceptive Advisors withdrew a net $685M in Q1 2026, closing 42 positions and reducing 33 holdings. Its most notable exit was Exact Sciences, an estimated $122M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Miscellaneous.
Against the trend, Perceptive Advisors opened a new position in Ionis Pharmaceuticals worth $37.8M.
- Perceptive Advisors's largest Q1 2026 buy was Ionis Pharmaceuticals: 504,000 shares worth $37.8M.
- Perceptive Advisors added most to Ascendis Pharma A/S in Q1 2026, an estimated $101M increase.
- Perceptive Advisors's biggest Q1 2026 reduction was Apogee Therapeutics, cutting an estimated $57.4M.
- Perceptive Advisors fully exited Exact Sciences in Q1 2026, selling an estimated $122M.
- Perceptive Advisors's ten largest holdings make up 51% of its $5.12B portfolio in Q1 2026.
- Perceptive Advisors opened 20 new positions and closed 42 in Q1 2026.
- Perceptive Advisors's portfolio value fell 8.8% quarter-over-quarter to $5.12B.
Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.